We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Greiner Bio-One

Download Mobile App





World's First Inactivated COVID-19 Vaccine Produces Antibodies in All Participants in Clinical Trial

By HospiMedica International staff writers
Posted on 25 Jun 2020
Print article
Illustration
Illustration
The world's first inactivated COVID-19 vaccine has produced antibodies in every participant in Phase I/II clinical trials, according to a news report by Science and Technology Daily.

The inactivated COVID-19 vaccine has been developed by the Wuhan Institute of Biological Products under the China National Biotec Group (CNBG) affiliated to the China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China). On April 12, the vaccine obtained the world's first clinical trial approval, and Phase I/II clinical trials were then launched for 66 consecutive days to obtain data on its safety and efficacy after administration of two injections. The study was designed to evaluate the safety and immunogenicity of the COVID-19 inactivated vaccine in healthy subjects aged from 18 to 59 for low, medium and high dosages and injections at intervals of 14, 21 and 28 days.

The study focused on the changes in cellular immunity after vaccination and explored vaccination procedures, immunization dosage, safety, immunogenicity and changes in antibody levels in vivo. Up to now, all the 1,120 subjects that took part in the Phase I/II clinical studies have completed two injections. The clinical trial results showed that the vaccination was safe without any serious adverse reaction, and after different procedures and different doses of vaccination were adopted, participants in the vaccine group all produced high titers of antibodies. For those aged 18-59 who received two medium-dose injections through the 14-day and 21-day interval procedures, they had a neutralizing antibody positive conversion rate of 97.6%. For those who received two medium-dose injections at an interval of 28 days, the neutralizing antibody positive conversion rate reached 100%. The CNBG is now actively developing overseas cooperation in the Phase III clinical research and has confirmed cooperative intentions with companies and institutions in various countries.

Related Links:
China National Pharmaceutical Group Co., Ltd.


Print article

Channels

Business

view channel
Illustration

Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience

Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online. The virtual healthcare... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.